P
USH2283HActiveUtilityPatentIndex 41

Vaccines for protecting against influenza

Assignee: STOEHR KLAUSPriority: Apr 27, 2009Filed: Apr 27, 2010Granted: Sep 3, 2013
Est. expiryApr 27, 2029(~2.8 yrs left)· nominal 20-yr term from priority
Inventors:STOEHR KLAUSDORMITZER PHILIPDEL GIUDICE GIUSEPPE
A61P 37/04A61P 31/16A61K 39/12A61K 2039/70C12N 2760/16234C12N 2760/16134A61K 39/145A61K 2039/55566A61K 39/39
41
PatentIndex Score
0
Cited by
194
References
4
Claims

Abstract

A vaccine containing a H1 subtype influenza A virus hemagglutinin is either unadjuvanted or is adjuvanted but not with an oil-in-water emulsion adjuvant. The vaccine is suitable for immunizing a patient against swine flu. The vaccine may be monovalent. The vaccine may include two different H1 subtype influenza A virus hemagglutinins, wherein (i) the first H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3 and (ii) the second H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 3 than to SEQ ID NO: 1. A monovalent vaccine may be administered in conjunction with a trivalent A/H1N1-A/H3N2 B seasonal influenza vaccine. Other embodiments are also disclosed, such as reassortant viruses.

Claims

exact text as granted — not AI-modified
The invention claimed is:  
     
       1. A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the two doses are administered from 1-6 weeks apart, and (b) each monovalent vaccine contains a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3. 
     
     
       2. A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the two doses are administered from 1-6 weeks apart, and (b) each monovalent vaccine contains a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ ID NO: 1. 
     
     
       3. A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3. 
     
     
       4. A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ ID NO: 1.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.